Last reviewed · How we verify

Ibuprofen bolus injection

Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology · FDA-approved active Small molecule

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Acute pain management, Fever reduction, Postoperative pain.

At a glance

Generic nameIbuprofen bolus injection
SponsorFederal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation, Fever
PhaseFDA-approved

Mechanism of action

As a nonsteroidal anti-inflammatory drug (NSAID), ibuprofen blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses, pain signaling, and fever regulation. The bolus injection formulation allows for rapid systemic delivery and faster onset of action compared to oral administration, making it suitable for acute pain and fever management in clinical settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results